Screener
PPH vs XBI
VanEck Pharmaceutical ETF vs State Street SPDR S&P Biotech ETF
Key differences
- XBI is significantly larger than PPH — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, XBI has delivered higher annualized returns.
- XBI has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PPH | XBI | |
|---|---|---|
| Annual cost (TER) | 0.36% | 0.35% |
| Fund size (AUM) | $966M | $8.3B |
| Since | 2011 | 2006 |
| Dividend yield | 2.12% | 0.34% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +24.5% | +66.6% |
| CAGR 3Y | +12.6% | +15.6% |
| CAGR 5Y | +9.8% | +0.9% |
| Sharpe 3Y | 0.63 | 0.54 |
| Volatility 1Y | 17.07% | 25.14% |
| Max drawdown | -29.70% | -63.89% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PPH and XBI
Explore further